

Voluntary Quarterly Release as of 30 September 2025

DARWIN AG

Darwin Group

in kEUR

P&L-Indicators*

3rd Quarter 2025 1st - 3rd Quarter 2025

Group Revenue	13,746	41,365
Gross Profit	6,429	17,360
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-286	-3,821
Earnings before Interest and Taxes (EBIT)	-959	-5,835
Financial Result	3,480	10,469
Earnings before Taxes (EBT)	2,521	4,634
Consolidated Net Income (EAT)	1,868	3,947
Earnings per share in EUR**	0,16	0,33

Balance Sheet Indicators*

30,09,2025

Total Assets	135,485
Equity	103,800
Equity Ratio (%)	76,6
Trade Receivables	4,610
Trade Payables	1,637
Cash and Cash Equivalents	9,880
Bank Liabilities	6,004

* unaudited, not reviewed by auditors

** Based on the share capital of 12,000,000 shares as of 30.09.2025

Dear Shareholders,

the third quarter of the 2025 financial year developed positively for the Darwin Group as expected. Quarterly revenue amounts to approximately €13.7 million and is therefore roughly on the level of the previous quarters. This revenue development reflects, on the one hand, a seasonally weaker performance of the Pharmaceuticals and Medical Products trading division and, on the other hand, strong growth in the genetic testing business, including personalized nutritional supplements and cosmetic products based on these tests.

This development is also clearly visible in the Group's earnings. The genetic testing division is approaching break-even as a result of revenue growth and the expiration of IT investments. Sustainable profitability of this division is expected from the beginning of the 2026 financial year. Accordingly, EBITDA and EBIT—although still negative—improved significantly in the third quarter. Based on the continued very strong financial result, the Group closes the quarter with a net profit after tax of approximately €1.9 million.

In the third quarter, important foundations for future revenue growth were laid. The now-signed distribution partnerships with M42 in the United Arab Emirates and the Hartlauer corporate group in Austria are the most visible examples of this. The M42 project in particular is expected to generate substantial revenue and earnings increases in the future.

Based on the strong quarterly results and the significant improvement in our commercial position, the Management Board remains very optimistic about the future.

Munich, 02 December 2025


Yours sincerely,

Darwin AG



Dr. Daniel Wallerstorfer

Founder and CEO



Felix Bausch

CIO

Consolidated Profit and Loss Account

	Q3 2025	Q1 - Q3 2025 EUR
1. Group revenue	13,746,247.61	41,365,109.26
2. Increase (decrease) in finished goods and work in process	-144,695.49	45,744.86
Total Output	13,601,552.12	41,410,854.12
3. Other operating income	1,216,815.72	4,786,374.44
4. Cost of Materials:		
a) Costs of raw materials, consumables, and supplies and of purchased goods	-8,324,706.59	-28,035,718.29
b) Costs for purchased services	-64,874.91	-801,791.47
5. Personnel expenses:		
a) Wages and salaries	-2,863,870.59	-9,294,346.87
b) Social security contributions, pension, support	-603,585.75	-2,048,468.19
6. Depreciation		
a) On intangible assets and property, plant & equipment	-673,822.64	-2,013,639.02
7. Other operating expenses	-3,246,868.85	-9,837,899.48
Operating result (EBIT)	-959,361.49	-5,834,634.76
8. Income from marketable securities	302,740.15	4,285,556.53
9. Other interest and similar income	293,657.83	920,387.67
10. Income from the disposal of and revaluation of financial assets and marketable securities	3,202,833.35	6,016,405.37
11. Depreciation of financial assets and marketable securities	-191,945.22	-342,880.81
12. Interest and similar expenses	-126,833.52	-410,515.34
13. Financial Result	3,480,452.59	10,468,953.42
14. Earnings before Taxes (EBT)	2,521,091.10	4,634,318.66
15. Income Taxes	-662,901.09	-737,637.52
16. Earnings after Taxes (EAT)	1,858,190.01	3,896,681.14
17. Other Taxes	-1,956.64	-2,954.96
18. Non-controlling interests	11,361.95	53,678.46
19. Consolidated net profit	1,867,595.32	3,947,404.64

Notes to the Consolidated Income Statement

Other operating income includes notional reversals of provisions amounting to €3.75 million. Based on current knowledge, the Management Board expects reversals of provisions totalling approximately €5 million by year-end for the 2025 financial year.

In the 3rd Quarter alone, other operating expenses include approximately €1.6 million related to development services for software systems, which will be completed in the fourth quarter of 2025. Considerably lower expenses are expected in this area in the following years.

The Darwin Group invests a substantial portion of its available financial reserves in broadly diversified equity portfolios. These also performed very well in the third quarter of 2025 and thus positively affected the financial result.

Consolidated Balance Sheet

ASSETS	30.09.2025	LIABILITIES & EQUITY	30.09.2025
A. Non-Current Assets	47,345,352.91	A. Equity	103,800,137.85
I. Intangible Assets	9,958,039.03	I. Subscribed Capital	12,000,000.00
1. Concessions, industrial property rights and similar rights and assets acquired for consideration, as well as licenses to such rights and assets	3,508,898.77	II. Capital Reserve	8,700,001.00
2. Goodwill	6,449,140.26	III. Retained Earnings	28,025,588.37
II. Property, Plant & Equipment	9,437,305.86	IV. Equity difference from currency translation	-9,551.22
1. Buildings	795,072.22	V. Consolidated Earnings	54,629,313.27
2. Technical Equipment/machines	3,127,893.61	VI. Non-controlling interests	454,786.43
3. Other equipment, fixtures and fittings	1,539,518.09		
4. Advance payments and assets under construction	3,974,821.94	B. Provisions	14,073,991.67
III. Financial Assets	27,950,008.02	I. Tax Provisions	8,003,059.27
1. Investments	1,300,005.02	II. Other Provisions	6,070,932.40
2. Loans to related Companies	2.00		
3. Other Loans	1.00	C. Liabilities	17,211,706.10
4. Securities held as fixed assets	26,650,000.00	1. Liabilities to banks	6,004,409.69
B. Current Assets	87,601,811.67	2. Advance payments received on orders	1,636,643.22
I. Inventories	12,873,188.41	3. Trade accounts payable	1,914,625.69
1. Raw materials, consumables, and supplies	9,284,964.35	4. Liabilities to participating interests	7,656,027.50
2. Finished goods and merchandise	2,027,878.99		
3. Advance payments on inventories	469,383.50		
4. Work in progress	1,090,961.57		
II. Receivables and other assets	21,397,048.82	D. . Deferred Liabilities	398,972.99
1. Trade receivables	4,609,727.12		
2. Other Assets	11,066,020.21		
3. Receivables from participating interests	5,721,301.49		
III. Marketable Securities	43,451,206.26		
IV. Cash and Cash Equivalents	9,880,368.18		
C. Deferred Assets	537,644.03		
Balance Sheet Total	135,484,808.61	Balance Sheet Total	135,484,808.61

Notes to the Consolidated Balance Sheet

The building shown under property, plant and equipment relates to the operating facility of MEDICOPHARM AG. All other premises used by the Group are rented. If the planned new building for Novogenia GmbH is realised, it will also be reflected in the consolidated balance sheet. Costs incurred to date for planning this new building are recorded under prepayments and assets under construction.

Receivables from related companies relate to loans granted to major shareholders of Darwin AG, which are secured by outstanding dividend entitlements of these shareholders. The dividend entitlements are reported under liabilities to related companies. These liabilities have decreased significantly based on a tax exemption certificate issued by the German Federal Central Tax Office to one shareholder in the third quarter.

Share capital amounted to 3,000,000 no-par value shares as of 30 June 2025. At an extraordinary general meeting on 13 August 2025, a stock split of 1:3 was resolved. The new shares were issued through the conversion of €9,000,000 from the capital reserve into share capital. The new shares were issued on 22 September 2025, increasing share capital to 12,000,000 no-par value shares.

DARWIN

Analyse. Learn. Solve.

Darwin AG

Brienner Straße 7
80333 München

investor.relations@darwin-biotech.com

www.darwin-biotech.com